Alan Forman
Direttore/Membro del Consiglio presso JBG SMITH PROPERTIES
Patrimonio netto: 80 928 $ in data 30/04/2024
Posizioni attive di Alan Forman
Società | Posizione | Inizio | Fine |
---|---|---|---|
JBG SMITH PROPERTIES | Direttore/Membro del Consiglio | 01/01/2017 | - |
Independent Dir/Board Member | 01/01/2017 | - | |
National Association of Corporate Directors (Virginia)
National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | Corporate Officer/Principal | - | - |
JBG SMITH Properties LP
JBG SMITH Properties LP Real Estate DevelopmentFinance Part of JBG SMITH Properties, JBG SMITH Properties LP is a company based in Bethesda, MD. JBG SMITH Properties LP was founded in 1957. The CEO is W. Matthew Kelly. | Direttore/Membro del Consiglio | - | - |
Vendite Istituzionali | - | - | |
Yale Investments Office | Direttore degli Investimenti | 01/10/1997 | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | 01/05/2023 | - |
Storia della carriera di Alan Forman
Precedenti posizioni note di Alan Forman
Società | Posizione | Inizio | Fine |
---|---|---|---|
Yale University Endowment
Yale University Endowment Investment Trusts/Mutual FundsMiscellaneous Since 1975, the Yale Corporation Investment Committee has been responsible for oversight of the Yale University Endowment. They are located in New Haven, Connecticut | Direttore degli Investimenti | 01/10/1997 | - |
Gestore di Portafoglio-Azioni | 01/10/1990 | 01/03/2022 | |
STEMLINE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 27/04/2015 | - |
Kimpton Group Holding LLC
Kimpton Group Holding LLC Hotels/Resorts/Cruise linesConsumer Services Kimpton Group Holding LLC operates hotels and restaurants. It is the parent company of Kimpton Hotels & Restaurants which is a collection of boutique hotels coupled with chef-driven restaurants. The company was founded in 1981 and is headquartered in San Francisco, CA | Direttore/Membro del Consiglio | - | - |
ACADIA REALTY TRUST | Direttore/Membro del Consiglio | 01/08/2002 | - |
Formazione di Alan Forman
Dartmouth College | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 12 |
Posizioni
Director/Board Member | 6 |
Chief Investment Officer | 2 |
Corporate Officer/Principal | 1 |
Settori
Finance | 4 |
Consumer Services | 4 |
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
ACADIA REALTY TRUST | Finance |
JBG SMITH PROPERTIES | Finance |
Aziende private | 7 |
---|---|
Yale University Endowment
Yale University Endowment Investment Trusts/Mutual FundsMiscellaneous Since 1975, the Yale Corporation Investment Committee has been responsible for oversight of the Yale University Endowment. They are located in New Haven, Connecticut | Miscellaneous |
Kimpton Group Holding LLC
Kimpton Group Holding LLC Hotels/Resorts/Cruise linesConsumer Services Kimpton Group Holding LLC operates hotels and restaurants. It is the parent company of Kimpton Hotels & Restaurants which is a collection of boutique hotels coupled with chef-driven restaurants. The company was founded in 1981 and is headquartered in San Francisco, CA | Consumer Services |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
National Association of Corporate Directors (Virginia)
National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | Commercial Services |
JBG SMITH Properties LP
JBG SMITH Properties LP Real Estate DevelopmentFinance Part of JBG SMITH Properties, JBG SMITH Properties LP is a company based in Bethesda, MD. JBG SMITH Properties LP was founded in 1957. The CEO is W. Matthew Kelly. | Finance |
Yale Investments Office | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Alan Forman
- Esperienza